Conclusion-Atenolol given from the end of the first trimester in patients with mild hypertension is associated with intrauterine growth retardation. When taken in conjunction with the results of a previous study in which methyldopa was given these findings indicate that benefit is unlikely to result from treating mild essential hypertension in pregnancy.
Introduction
The value of antihypertensive drugs in managing mild to moderate essential hypertension during pregnancy is unclear. A study by Redman et al in the 1970s found that the outcome of pregnancy was better in a group who received methyldopa than in a group who did not receive any treatment.' It was difficult, however, to ascribe the better outcome to the reduction in blood pressure, and Redman et al concluded that perhaps an unidentified pharmacological effect of methyldopa was responsible.
Extrapolating from this hypothesis, we argued that if it was a reduction in blood pressure that was responsible for the better outcome then a different antihypertensive agent would have the same beneficial effect. We showed that atenolol given to women who develop hypertension in the third trimester successfully lowers blood pressure and usefully prolongs pregnancy, with a consequent reduction in perinatal morbidity.2 In the present study we assessed the value of atenolol in women whose pregnancies were complicated by essential hypertension.
Patients and methods
The randomised, placebo controlled, double blind study was approved by the research and ethical committee of Greater Glasgow Health Board Northern District. Thirty three women who were consecutively referred to the obstetric medical clinics at Stobhill General Hospital and the Queen Mother's Hospital for management of essential hypertension were studied. The criteria for entry to the study were either a systolic blood pressure between 140 and 170 mm Hg or a diastolic blood pressure (Korotkoff phase V) between 90 and 110 mm Hg on two occasions separated by at least 24 hours. Recruitment took place at between 12 and 24 weeks' gestation. Women were excluded from the study if they had any of the usual contraindications to use of a 3 blocker.
For those women who received active treatment the starting dose of atenolol was 50 mg daily and the number of tablets was increased at each visit until either the blood pressure was <140/90 mm Hg or a dose of 200 mg daily was reached. The patients were seen at intervals of four weeks until they were 28 weeks pregnant, then every two weeks until they were 36 weeks pregnant, and then weekly until delivery. Babies were assessed at birth and at 12 months of age.
Data were analysed by t test. In the case of blood pressure, all readings after entry to the trial were averaged and the means for the two groups were compared. We had originally intended to recruit a larger number of women, but during the course of the study the principal investigator (PCR) left Glasgow and we thought it impractical to continue. The treatment codes were not broken until the last patient delivered.
Results Three women in the placebo group were withdrawn from the study, because of inadequate control of blood pressure (two) and breathlessness (one), and one woman in the atenolol group changed her mind about participating before taking any tablets. No additional drugs were used by the 29 women who remained in the study. Analysis of data on these 29 patients (15 treated with atenolol and 14 with placebo) showed that the two groups were well matched with regard to average gestation at entry (15-8 and 15-9 weeks respectively) and average blood pressure at entry (144/86 and 148/86 mm Hg respectively). The table shows the patients' blood pressure after entry to the trial. Mean diastolic pressure was significantly reduced by atenolol, but the effect on systolic pressure was marginal.
One stillbirth occurred in the atenolol group. Figure  1 shows the birth weights of the babies and figure 2 the placental weights. The babies in the atenolol group often of pregnancies with many major complications and it was difficult to distinguish between effects of the disease and effects of the drugs given.
Prospective studies have given a uniformly different picture with regard to fetal growth from that given by the early reports. Small uncontrolled studies of propranolol in hypertension,' a study of a series of women taking propranolol for hypertrophic obstructive cardiomyopathy,6 and randomised comparisons of oxprenolol with methyldopa79 suggested that growth retardation was not a feature of treatment with I3 blockers during pregnancy. In two double blind, randomised, placebo controlled studies of atenolol2 and metoprolol'°in pregnancy induced hypertension no difference in average birth weight was found between the groups given placebo and active treatment, and there was no excess of babies who were small for gestational age in groups given the 1 blockers.
In contrast, our study provides unequivocal evidence that atenolol given to manage mild essential hypertension is associated with impaired fetal growth. The mechanism of this effect and the reasons for the difference in outcome between this and our earlier trial of atenolol2 are not clear, but several points are relevant.
Firstly, the women who entered this study had fairly mild hypertension. In particular, our recruitment of women who met either the criterion for systolic pressure or the criterion for diastolic pressure, but not necessarily both, resulted in several patients having a diastolic pressure <90 mm-Hg at the start of the study. The women in our previous study of pregnancy induced hypertension had more severe, as well as mechanistically different, hypertension. Thus a possible explanation of our findings is that we were excessively lowering a blood pressure that was only slightly raised and that fetal perfusion was adversely affected. The blood pressures at entry, however, were not materially different from those in Redman et al's study of methyldopa, in which the group given early treatment had an average blood pressure on entry of 142/88 mm Hg and similar reductions in pressure seem to have occurred.' As growth retardation was not seen in that study we infer that the atenolol itself, rather than the lowering of the blood pressure, was responsible for the unsatisfactory response to treatment.
Secondly, the women entered the present study at a mean of 15 9 (SD [2] [3] [4] [5] [6] [7] [8] weeks' gestation whereas the women entered our study of pregnancy induced hypertension at 33-8 (4 9) weeks' gestation. Thus the women in the present study received treatment for about 18 weeks longer than those in our previous trial. Indeed, all the studies referred to above in which an adverse effect on growth was not seen (with the possible exception of the study of patients with cardiomyopathy, in which gestation was not stated) began treatment in the third trimester. The duration of treatment may therefore be a factor in the growth retardation.
Thirdly, we reported in our study of pregnancy induced hypertension that treatment with atenolol is associated with a significant and progressive fall in human placental lactogen concentration.2 We were unable to correlate this fall in concentration with the outcome of pregnancy and could not offer any explanation other than to discount interference with the assay in vitro. With the changing emphasis from biochemical to biophysical methods of fetal assessment human placental lactogen concentration is less commonly measured now than when we did our earlier study and we did not measure it in the present study.
We tended previously to discount the falling human placental lactogen concentration, though we accepted that it was unexplained, but our observations on fetal growth in the present study add new relevance to it. As human placental lactogen concentration is a measure, albeit of limited value, of placental function possibly atenolol impairs placental physiology in some way. The consequences of this impairment could be evident biochemically in the short term and become clear clinically with longer term treatment. Should this be the case, the mechanism by which atenolol exerts this effect is unclear. The effect of atenolol on variables of Doppler waveform indices is undecided, with present evidence being conflicting.'3 14 If our observations are the result of an effect of atenolol similar consequences would probably result from the use of any 13 blocker with a similar pharmacodynamic profile. Our findings do not enable us to speculate on whether a 13 blocker with intrinsic sympathomimetic activity would have a similar effect. The difference in the weight of the children between the two groups had resolved by 12 months, indicating that the changes were reversible.
The importance of the drug treatment in the one stillbirth that occurred is difficult to assess because the woman concerned had also had a stillbirth in her previous pregnancy, when she did not receive any drug treatment.
In conclusion, we are left with substantial uncertainties about the value of treating mild essential hypertension during pregnancy. The earlier findings of Redman et al' did not suggest a simple relation, if any, between controlling blood pressure with methyldopa and an improved outcome of pregnancy. The present study suggests that using atenolol in patients with mild essential hypertension leads to growth retardation. We therefore do not recommend the use of a 13 blocker to treat hypertension early in pregnancy and suggest that benefits are unlikely to accrue from treating the milder forms of essential hypertension in pregnancy. This 
